ATC Group: V08C Magnetic resonance imaging contrast media

Gadobenic acid is a paramagnetic contrast agent for use in diagnostic magnetic resonance imaging (MRI) of the liver.

Gadobutrol is a gadolinium-based, hydrophilic, macrocyclic, electrically neutral contrast agent used in contrast-enhanced MRI (CE-MRI).

Gadodiamide is a paramagnetic contrast agent (GBCA), with imaging activity upon magnetic resonance imaging (MRI). Gadodiamide activity enhances the visualization of the tissues.

Gadofosveset is a formulation of a stable gadolinium diethylenetriaminepentaacetic acid (GdDTPA) chelate substituted with a diphenylcyclohexylphosphate group (gadofosveset trisodium), for use in magnetic resonance imaging (MRI). Gadofosveset binds reversibly to human serum albumin.

Gadopentetic acid is a paramagnetic contrast agent for magnetic resonance imaging.

Gadopiclenol is a paramagnetic agent for Magnetic Resonance Imaging (MRI). The contrast-enhancing effect is mediated by gadopiclenol which is a macrocyclic non-ionic complex of gadolinium, the active moiety which enhances the relaxation rates of water protons in its vicinity in the body, leading to an increase in signal intensity (brightness) of tissues.

Gadoteric acid has paramagnetic properties allowing MRI contrast enhancement. It has no specific pharmacodynamic activity and is biologically very inert.

Gadoteridol is a non-ionic paramagnetic contrast medium for Magnetic Resonance Imaging. Gadoteridol is for diagnostic use only.

Gadoversetamide is a chelate containing gadolinium – which has paramagnetic properties and is responsible for the contrast enhancement effect in MRI – and the ligand versetamide. Gadoversetamide after intravenous administration, equilibrates rapidly within the extracellular fluid/space and is eliminated primarily by glomerular filtration.

Gadoxetic acid is a paramagnetic contrast agent for magnetic resonance imaging. The contrast-enhancing effect is mediated by gadoxetate (Gd EOB DTPA), an ionic complex consisting of gadolinium (III) and the ligand ethoxybenzyl-diethylenetriamine-pentaacetic acid (EOB-DTPA).

Mangafodipir is a chelate containing the metal manganese – which has paramagnetic properties and is responsible for the contrast enhancement effect in MRI – and the ligand fodipir (dipyridoxyl diphosphate). Manganese is preferentially taken up by normal liver parenchyma and also in the pancreas so that contrast enhancement between abnormal and normal tissue can be expected.